{"entity":{"id":"paper-neyaz-pdl1-gallbladder-histopathology-2018","kind":"paper","name":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","aka":[],"tldr":"In 174 Indian gallbladder cancers, about a quarter had PD-L1 on tumour cells and a quarter on immune cells, more so in higher-grade tumours, but PD-L1 did not predict survival.","summary":"174 cases of gallbladder carcinoma were evaluated for PD-L1 expression with the SP263 clone on tissue microarrays, at cut-offs of 1%, 10% and 50% in tumour cells and in tumour-infiltrating lymphocytes, and correlated with clinicopathological characteristics and survival. Mean age was 49.9 years, the male to female ratio 1 to 2.9, and 73.6% presented with stage 3 or 4 disease.\n\nTumour cells expressed PD-L1 in 23.0% of cases and tumour-infiltrating lymphocytes in 24.1%; at cut-offs of 10% and 50%, 14.9% and 7.5% of cases were positive. Tumour proportion score was associated with histological type, histological and nuclear grade, nodal metastasis, higher stage and tumour-infiltrating lymphocytes. Paired lymph node metastases showed discordantly higher PD-L1 than primaries. Overall survival was not associated with PD-L1 expression (P = 0.546).","asOf":"2026-09-24","links":[{"label":"Neyaz et al., Histopathology 2018: PD-L1 (SP263) in 174 Indian gallbladder cancers","url":"https://doi.org/10.1111/his.13669"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29882997/"}],"tags":[],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["ihc","tils"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Histopathology","year":2018,"doi":"10.1111/his.13669","pmid":"29882997","authors":"Neyaz A, Husain N, Kumari S, et al.","paperType":"observational","findings":["PD-L1 on tumour cells in 23.0% at 1%, 14.9% at 10% and 7.5% at 50%; on immune cells in 24.1% (SP263).","Associated with histological type and grade, nuclear grade and nodal metastasis; higher in nodal metastases than primaries.","No association with overall survival (P = 0.546)."],"whatItMeans":"The largest PD-L1 series from a high-incidence country; the one-in-four figure is the number quoted for gallbladder cancer, though the Western series with a different clone found fewer. No biliary approval uses PD-L1 to select patients.","caveats":["Tissue microarrays sample a small core of heterogeneous tumours.","SP263 clone and tumour-cell scoring are not interchangeable with 22C3 CPS."],"changedPractice":false,"participants":174},"route":"/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"term":[{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"biomarker":[{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/"}]}}